Shares of Amylyx Pharmaceuticals (AMLX) nosedived 82.2% on Mar 8 after management announced topline results from the phase III PHOENIX study evaluating Relyvrio (AMX0035) for the treatment of amyotrophic lateral sclerosis (“ALS”). The study did not meet its primary or secondary endpoints. The PHOENIX study failed to achieve statistical significance in the primary endpoint of the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) total score following 48 weeks of treatment with Relyvrio ...